UY24430A1 - Procedimiento para preparar vacuna contra tumores - Google Patents
Procedimiento para preparar vacuna contra tumoresInfo
- Publication number
- UY24430A1 UY24430A1 UY24430A UY24430A UY24430A1 UY 24430 A1 UY24430 A1 UY 24430A1 UY 24430 A UY24430 A UY 24430A UY 24430 A UY24430 A UY 24430A UY 24430 A1 UY24430 A1 UY 24430A1
- Authority
- UY
- Uruguay
- Prior art keywords
- patient
- peptides
- tumor cells
- cells
- tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 210000004881 tumor cell Anatomy 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 6
- 210000004027 cell Anatomy 0.000 abstract 3
- 102000054766 genetic haplotypes Human genes 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 108010039918 Polylysine Proteins 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108090000901 Transferrin Proteins 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 229920000656 polylysine Polymers 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a un procedimiento para la preparación de una vacuna contra tumores que contiene células tumorales, para su administración a un paciente. La misma se caracteriza porque las células tumorales, que por sí misma, presentan en el contexto de HLA péptidos derivados de antígenos de tumores y de las que al menos una parte expresa por lo menos un haplotipo MCH-I (MCH: complejo de histocompatibilidad principal) del paciente, se tratan con uno o varios péptido varios péptidos, que: a) funcionan como ligandos para el haplotipo MHC-I que es común al paciente y a las células tumorales de la vacuna, y son diferentes de péptidos que se derivan de proteínas que son expresadas por células del paciente o, que b) funcionan como ligandos para el haplotipo MHC-I que es común al del paciente y al de las células tumorales de la vacuna, y se derivan de antígenos tumorales que son expresados por células del paciente, incubando las células tumorales con uno o varios péptidos a) y/o b) un tiempo y en una cantidad, en presencia de un policatión orgánico hasta que los péptidos estén fijados a las células tumorales de modo que, en el contexto con las células tumorales del sistema inmune del paciente, son reconocidos como extrañas y desencadenan una respuesta inmune celular. Como policatión se emplea polilisina. Dicho policatión se emplea en forma parcialmente conjugada y está conjugado con transferrina. Se caracteriza también porque las células se tratan además en presencia de ADN (un plásmido).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19543649A DE19543649C2 (de) | 1995-11-23 | 1995-11-23 | Tumorvakzine und Verfahren zu ihrer Herstellung |
| DE19607044A DE19607044A1 (de) | 1996-02-24 | 1996-02-24 | Tumorvakzine und Verfahren zu ihrer Herstellung |
| UY24367A UY24367A1 (es) | 1995-11-23 | 1996-11-19 | Vacunas contra tumores y procedimiento para su produccion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY24430A1 true UY24430A1 (es) | 1997-07-01 |
Family
ID=26020603
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY24367A UY24367A1 (es) | 1995-11-23 | 1996-11-19 | Vacunas contra tumores y procedimiento para su produccion |
| UY24430A UY24430A1 (es) | 1995-11-23 | 1997-01-03 | Procedimiento para preparar vacuna contra tumores |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY24367A UY24367A1 (es) | 1995-11-23 | 1996-11-19 | Vacunas contra tumores y procedimiento para su produccion |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20020085997A1 (es) |
| EP (1) | EP0866851A1 (es) |
| JP (1) | JP2000502052A (es) |
| KR (1) | KR19990067653A (es) |
| CN (1) | CN1202931A (es) |
| AR (1) | AR004341A1 (es) |
| AU (1) | AU720131B2 (es) |
| BG (1) | BG62999B1 (es) |
| BR (1) | BR9611466A (es) |
| CA (1) | CA2238176A1 (es) |
| CO (1) | CO4520254A1 (es) |
| CZ (1) | CZ158998A3 (es) |
| EE (1) | EE03778B1 (es) |
| HU (1) | HUP0000318A3 (es) |
| NO (1) | NO982329D0 (es) |
| NZ (1) | NZ322910A (es) |
| PL (1) | PL188537B1 (es) |
| RO (1) | RO115275B1 (es) |
| RU (1) | RU2206329C2 (es) |
| SK (1) | SK66998A3 (es) |
| TR (1) | TR199800912T2 (es) |
| TW (1) | TW514530B (es) |
| UY (2) | UY24367A1 (es) |
| WO (1) | WO1997019169A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO4600681A1 (es) † | 1996-02-24 | 1998-05-08 | Boehringer Ingelheim Pharma | Composicion farmaceutica para la modulacion inmunitaria |
| JP2001522226A (ja) | 1997-01-31 | 2001-11-13 | リサーチ コーポレイション テクノロジーズ インコーポレイテッド | セミ−同種異系細胞での癌の免疫療法 |
| DE69731950T2 (de) * | 1997-08-22 | 2005-05-19 | Science Park Raf S.P.A. | Tumorvakzinierung mittels Verwendung autologer oder HLA-verwandter Antigen präsentierender Zellen (APC), die mit einem Tumorantigen sowie einem eine Immunantwort hervorrufenden Fremdantigen transduziert sind |
| CA2322660A1 (en) * | 1998-03-20 | 1999-09-23 | Genzyme Corporation | Enhanced anti-tumor immunity |
| US7014848B1 (en) | 1998-03-20 | 2006-03-21 | Genzyme Corporation | Enhanced anti-tumor immunity |
| FR2807661A1 (fr) * | 2000-04-14 | 2001-10-19 | Univ Nantes | Agent et procede pour la simulation de lymphocytes t specifiques et lymphocytes t obtenus |
| CA2476995A1 (en) * | 2001-09-18 | 2003-03-27 | Kyogo Itoh | Method of detecting cellular immunity and application thereof to drugs |
| GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| CN1315536C (zh) * | 2002-09-13 | 2007-05-16 | 李进 | 肿瘤抗原疫苗及其制备方法和疫苗组合物 |
| GB0224442D0 (en) | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
| ATE475430T1 (de) * | 2003-08-25 | 2010-08-15 | Univax Llc | Präventive krebsvakzine auf basis des boris (brother of regulator of imprinted sites) moleküls |
| US7674456B2 (en) * | 2004-06-14 | 2010-03-09 | Charles Wiseman | Breast cancer cell lines and uses thereof |
| WO2006105255A2 (en) * | 2005-03-29 | 2006-10-05 | The Board Of Trustees Of The University Of Illinois | Cancer vaccines and therapeutic methods |
| EP1806358B1 (en) * | 2005-09-05 | 2010-03-17 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| WO2011101465A1 (en) | 2010-02-19 | 2011-08-25 | Intercell Ag | Ic31 nanoparticles |
| ES2729759T3 (es) * | 2012-07-12 | 2019-11-06 | Persimmune Inc | Vacunas contra el cáncer personalizadas y terapias celulares inmunitarias adoptivas |
| EP3431595A4 (en) | 2016-03-15 | 2019-11-20 | Repertoire Genesis Incorporation | MONITORING AND DIAGNOSIS FOR IMMUNOTHERAPY AND DESIGN FOR THERAPEUTICS |
| WO2018208856A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
| EP3976075A4 (en) | 2019-05-30 | 2023-08-16 | Gritstone bio, Inc. | MODIFIED ADENOVIRUS |
| KR20230046313A (ko) | 2020-08-06 | 2023-04-05 | 그릿스톤 바이오, 인코포레이티드 | 다중에피토프 백신 카세트 |
| CA3211645A1 (en) * | 2021-03-12 | 2022-09-15 | Erika VON EUW | Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235525B1 (en) * | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
| EP0569678A3 (en) * | 1992-03-13 | 1994-10-26 | Yeda Res & Dev | Double transfectants of MHC genes as cellular vaccines for immunoprevention of tumor metastasis. |
-
1996
- 1996-11-19 UY UY24367A patent/UY24367A1/es not_active IP Right Cessation
- 1996-11-21 CN CN96198493A patent/CN1202931A/zh active Pending
- 1996-11-21 PL PL96326756A patent/PL188537B1/pl not_active IP Right Cessation
- 1996-11-21 SK SK669-98A patent/SK66998A3/sk unknown
- 1996-11-21 AU AU76947/96A patent/AU720131B2/en not_active Ceased
- 1996-11-21 TR TR1998/00912T patent/TR199800912T2/xx unknown
- 1996-11-21 KR KR1019980703681A patent/KR19990067653A/ko not_active Application Discontinuation
- 1996-11-21 CA CA002238176A patent/CA2238176A1/en not_active Abandoned
- 1996-11-21 BR BR9611466A patent/BR9611466A/pt not_active Application Discontinuation
- 1996-11-21 JP JP9519395A patent/JP2000502052A/ja not_active Abandoned
- 1996-11-21 RO RO98-00985A patent/RO115275B1/ro unknown
- 1996-11-21 CZ CZ981589A patent/CZ158998A3/cs unknown
- 1996-11-21 US US09/077,214 patent/US20020085997A1/en not_active Abandoned
- 1996-11-21 NZ NZ322910A patent/NZ322910A/xx unknown
- 1996-11-21 RU RU98111622/14A patent/RU2206329C2/ru not_active IP Right Cessation
- 1996-11-21 WO PCT/EP1996/005126 patent/WO1997019169A1/de not_active Application Discontinuation
- 1996-11-21 EE EE9800161A patent/EE03778B1/xx not_active IP Right Cessation
- 1996-11-21 HU HU0000318A patent/HUP0000318A3/hu unknown
- 1996-11-21 EP EP96939870A patent/EP0866851A1/de not_active Withdrawn
- 1996-11-22 CO CO96061701A patent/CO4520254A1/es unknown
- 1996-11-22 AR ARP960105291A patent/AR004341A1/es not_active Application Discontinuation
- 1996-11-23 TW TW085114455A patent/TW514530B/zh not_active IP Right Cessation
-
1997
- 1997-01-03 UY UY24430A patent/UY24430A1/es not_active IP Right Cessation
-
1998
- 1998-05-08 BG BG102439A patent/BG62999B1/bg unknown
- 1998-05-22 NO NO982329A patent/NO982329D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0000318A2 (hu) | 2000-06-28 |
| WO1997019169A1 (de) | 1997-05-29 |
| AU720131B2 (en) | 2000-05-25 |
| JP2000502052A (ja) | 2000-02-22 |
| NO982329D0 (no) | 1998-05-22 |
| EE9800161A (et) | 1998-12-15 |
| CN1202931A (zh) | 1998-12-23 |
| KR19990067653A (ko) | 1999-08-25 |
| CO4520254A1 (es) | 1997-10-15 |
| TW514530B (en) | 2002-12-21 |
| BR9611466A (pt) | 1999-05-18 |
| PL326756A1 (en) | 1998-10-26 |
| SK66998A3 (en) | 1998-12-02 |
| US20020085997A1 (en) | 2002-07-04 |
| BG102439A (en) | 1999-01-29 |
| RU2206329C2 (ru) | 2003-06-20 |
| AR004341A1 (es) | 1998-11-04 |
| RO115275B1 (ro) | 1999-12-30 |
| BG62999B1 (bg) | 2001-01-31 |
| EP0866851A1 (de) | 1998-09-30 |
| NZ322910A (en) | 2000-05-26 |
| UY24367A1 (es) | 2000-10-31 |
| CA2238176A1 (en) | 1997-05-29 |
| HUP0000318A3 (en) | 2002-02-28 |
| PL188537B1 (pl) | 2005-02-28 |
| AU7694796A (en) | 1997-06-11 |
| EE03778B1 (et) | 2002-06-17 |
| TR199800912T2 (xx) | 1998-08-21 |
| CZ158998A3 (cs) | 1999-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY24430A1 (es) | Procedimiento para preparar vacuna contra tumores | |
| CY1115749T1 (el) | Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια | |
| US7528224B1 (en) | Peptide for triggering an immune reaction against tumor cells | |
| CN101824400B (zh) | 一种放大增殖抗原特异性t细胞的方法 | |
| BR9306984A (pt) | Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo | |
| de Visser et al. | Tracing and characterization of the low‐avidity self‐specific T cell repertoire | |
| Bauer et al. | Polypeptides of avian RNA tumor viruses: II. Serological characterization | |
| Saalmüller et al. | Characteristics of porcine T lymphocytes and T-cell lines | |
| RU2017127024A (ru) | Герпесвирус с измененным спектром мишеней, содержащий гибридный гликопротеин н | |
| Rock et al. | Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant. | |
| CN101512000B (zh) | 生产寡肽的方法 | |
| EA012520B1 (ru) | Способ получения цитотоксических лимфоцитов | |
| CA2494304A1 (en) | Materials and methods relating to improved vaccination strategies | |
| ATE237691T1 (de) | Rekombinantes pockenvirus der infektiösen peritonitis der katze, dessen zusammensetzungen und methoden zur herstellung und verwendung | |
| EP0236977A3 (en) | Bovine virus diarrhea and hog cholera vaccines | |
| AR009365A1 (es) | Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno | |
| CN102159240A (zh) | 基于狂犬病毒的重组免疫避孕组合物及其使用方法 | |
| SE9903534D0 (sv) | Vaccin | |
| Morey et al. | Immunohistochemical localization of neurotropic ecotropic murine leukemia virus in moribund mice | |
| RU2660566C2 (ru) | Иммунизация вектором на основе вируса бешенства, экспрессирующим чужеродный белковый антиген | |
| Li et al. | Immunogenicity assessment of rift valley fever virus virus-like particles in BALB/c mice | |
| HU227667B1 (en) | Novel expression vectors and uses thereof | |
| Clydesdale et al. | Contraception in mice immunized with recombinant zona pellucida subunit 3 proteins correlates with Th2 responses and the levels of interleukin 4 expressed by CD4+ cells | |
| Kast et al. | In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes | |
| Mohd-Lila et al. | The application of naked DNA plasmid (DrZP3) and recombinant adenovirus (Ad-rZP3) in rat animal model to determine comparative efficacy of ZP3-Immunocontraceptive vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| VENC | Patent expired |
Effective date: 20170103 |